Cancer Therapy : Preclinical Cisplatin-Induced Renal Injury Is Independently Mediated by OCT 2 and p 53

Purpose: Tubular secretion of cisplatin is abolished in mice deficient for the organic cation transporters Oct1 and Oct2 (Oct1/2 / mice), and these animals are protected from severe cisplatin-induced kidney damage. Since tubular necrosis is not completely absent in Oct1/2 / mice, we hypothesized that alternate pathways are involved in the observed injury. Experimental Design: Studies were done in wild-type, Oct1/2 / , or p53-deficient animals, all on an FVB background, receiving cisplatin intraperitoneally at 15 mg/kg. Cisplatin metabolites were analyzed usingmass spectrometry, and gene expressionwas assessedusingAffymetrixmicroarrays andRT-PCR arrays. Results: KEGG pathway analyses on kidneys from mice exposed to cisplatin revealed that the most significantly altered genes were associated with the p53 signaling network, including Cdnk1a andMdm2, in both wild-type (P 1⁄4 2.40 10 ) and Oct1/2 / mice (P 1⁄4 1.92 10 ). This was confirmed by demonstrating that homozygosity for a p53-null allele partially reduced renal tubular damage, whereas loss of p53 in Oct1/2 / mice (p53 / /Oct1/2 / ) completely abolished nephrotoxicity. We found that pifithrin-a, an inhibitor of p53-dependent transcriptional activation, inhibits Oct2 and can mimic the lack of nephrotoxicity observed in p53 / /Oct1/2 / mice. Conclusions: These findings indicate that (i) the p53 pathway plays a crucial role in the kidney in response to cisplatin treatment and (ii) clinical exploration of OCT2 inhibitors may not lead to complete nephroprotection unless the p53 pathway is simultaneously antagonized. Clin Cancer Res; 20(15); 1–10.

[1]  A. Gibson,et al.  Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance , 2013, Clinical pharmacology and therapeutics.

[2]  Taosheng Chen,et al.  146 Identification of Tyrosine Kinase Inhibitors as Modulators of OCT2 Function , 2012 .

[3]  Jing Zhang,et al.  Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[4]  Minoru Yoshida,et al.  Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events , 2012, Clinical and Experimental Nephrology.

[5]  M. Relling,et al.  Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients , 2012, Clinical Cancer Research.

[6]  Shuang Huang,et al.  Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. , 2011, The Journal of clinical investigation.

[7]  F. Zunino,et al.  Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors. , 2011, Bioorganic & medicinal chemistry.

[8]  Jia Yu,et al.  Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. , 2010, Biological & pharmaceutical bulletin.

[9]  R. Franke,et al.  Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting , 2010, Clinical Cancer Research.

[10]  R. Franke,et al.  Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase , 2010, Clinical Cancer Research.

[11]  H. Koepsell,et al.  Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. , 2010, The American journal of pathology.

[12]  A. Sparreboom,et al.  Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin‐Induced Nephrotoxicity , 2009, Clinical pharmacology and therapeutics.

[13]  R. Murphy,et al.  The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. , 2009, American journal of physiology. Renal physiology.

[14]  J. Verweij,et al.  Interaction of Cisplatin with the Human Organic Cation Transporter 2 , 2008, Clinical Cancer Research.

[15]  F. Zunino,et al.  Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. , 2008, Neoplasia.

[16]  L. Benson,et al.  Cisplatin and dimethyl sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity. , 2008, Neurotoxicology.

[17]  Z. Dong,et al.  Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. , 2008, Kidney international.

[18]  Shuang Huang,et al.  ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis* , 2008, Journal of Biological Chemistry.

[19]  J. Megyesi,et al.  Activation and involvement of p53 in cisplatin-induced nephrotoxicity. , 2007, American journal of physiology. Renal physiology.

[20]  A. C. Santos,et al.  Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria , 2007, Archives of Toxicology.

[21]  S. Masuda,et al.  Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family) , 2006, Journal of Pharmacology and Experimental Therapeutics.

[22]  Shuzhong Zhang,et al.  Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.

[23]  S. Masuda,et al.  Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. , 2005, Biochemical pharmacology.

[24]  T. Ludwig,et al.  Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. , 2005, The American journal of pathology.

[25]  R. Gary,et al.  The p53 inhibitor pifithrin-alpha forms a sparingly soluble derivative via intramolecular cyclization under physiological conditions. , 2005, Molecular pharmaceutics.

[26]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[27]  Paul Workman,et al.  An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. , 2005, Molecular cancer therapeutics.

[28]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[29]  M. J. van den Bent,et al.  Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients , 2003, British Journal of Cancer.

[30]  R. Salvi,et al.  Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. , 2003, Neuroscience.

[31]  P. Devarajan,et al.  Cisplatin nephrotoxicity: molecular mechanisms. , 2003, Cancer therapy.

[32]  D. Barfuss,et al.  Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl-L-cysteine-cDDP by TEA and PAH in the renal proximal tubule , 2003, Cancer Chemotherapy and Pharmacology.

[33]  V. Anisimov,et al.  [Susceptibility of wild and knockout p53 FVB/N line mice to benz(a)pyrene-induced subcutaneous sarcoma]. , 2002, Voprosy onkologii.

[34]  G. Ramesh,et al.  TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. , 2002, The Journal of clinical investigation.

[35]  J. Everitt,et al.  Nephrotoxicity and hepatotoxicity induced by inhaled bromodichloromethane in wild-type and p53-heterozygous mice. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  M V Chernov,et al.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.

[37]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[38]  G. Koren,et al.  Renal handling of cisplatin: interactions with organic anions and cations in the dog. , 1991, Clinical and investigative medicine. Medecine clinique et experimentale.

[39]  C. Coleman,et al.  The use of probenecid as a chemoprotector against cisplatin nephrotoxicity , 1991, Cancer.

[40]  M. Weiner,et al.  Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. , 1984, Cancer research.

[41]  D. Ross,et al.  Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid. , 1979, Cancer treatment reports.